1h Free Analyst Time
The primary biliary cholangitis therapeutics market is forecasted to grow by USD 346.85 mn during 2023-2028, accelerating at a CAGR of 8.75% during the forecast period. The report on the primary biliary cholangitis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by emergence of telehealth and remote monitoring, rising investments and developments in healthcare industry, and increase in product launches in primary biliary cholangitis therapeutics market.
The primary biliary cholangitis therapeutics market is segmented as below:
By Type
- Primary drug
- Secondary drug
By Distribution Channel
- Drug stores and retail pharmacies
- Hospital pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the primary biliary cholangitis therapeutics market covers the following areas:
- Primary biliary cholangitis therapeutics market sizing
- Primary biliary cholangitis therapeutics market forecast
- Primary biliary cholangitis therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global primary biliary cholangitis therapeutics market: Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing demand for R&D due to government healthcare expenditure.'
According to the report, one of the major drivers for this market is the emergence of telehealth and remote monitoring.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Alkem Laboratories Ltd.
- Eli Lilly and Co.
- GENFIT SA
- Glenmark Pharmaceuticals Ltd.
- ICE S.p.a.
- Intercept Pharmaceuticals Inc.
- Ipsen Pharma
- Leeford Healthcare Ltd.
- NGM Biopharmaceuticals Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Lifesciences Ltd.